Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy

Published:2020-07 Issue:4 Volume:21 Page:341-348
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Weissferdt Annikka,Pataer Apar,Vaporciyan Ara A.,Correa Arlene M.,Sepesi Boris,Moran Cesar A.,Wistuba Ignacio I.,Roth Jack A.,Shewale Jitesh Baban,Heymach John V.,Kalhor Neda,Cascone Tina,Hofstetter Wayne L.,Lee J. Jack,Swisher Stephen G.

Funder

National Institutes of Health

Cancer Center

Homer Flower Research

Charles Rogers Gene Therapy

Margaret Wiess Elkins Endowed Research

Flora and Stuart Mason Lung Cancer Research

Phalan Thoracic Gene Therapy

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer;Roth;Lung Cancer,1998

2. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial;Rosell;Lung Cancer,1999

3. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team;Pisters;J Thorac Cardiovasc Surg,2000

4. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer;Depierre;J Clin Oncol,2002

5. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy;Pataer;J Thorac Oncol,2012

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC;Journal of Thoracic Oncology;2024-07

2. Immune checkpoint inhibition in early-stage non-small cell lung cancer;Lung Cancer;2024-07

3. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC;BMC Pulmonary Medicine;2024-05-23

4. Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma;BMC Cancer;2024-05-13

5. Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma;Frontiers in Oncology;2024-04-12